Safety and Efficacy of Istradefylline in Parkinson’s Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials
Istradefylline treatment resulted in greater reductions in total "OFF" hours/day and increases in "ON" time without troublesome dyskinesia than did placebo, regardless of the presence or absence of preexisting dyskinesia.
Authors
- Rajesh Pahwa (ORCID: https://orcid.org/0000-0003-3176-6466)
- Nobutaka Hattori (ORCID: https://orcid.org/0000-0002-2034-2556)
- Fabrizio Stocchi (ORCID: https://orcid.org/0000-0002-5763-0033)
- Lawrence Elmer
- Lia Kostiuk
- Olivier Rascol (ORCID: https://orcid.org/0000-0002-1410-6397)
- Kapil D. Sethi (ORCID: https://orcid.org/0000-0002-6037-8895)
- Stuart Isaacson (ORCID: https://orcid.org/0000-0002-9914-5706)
- Yu Nakajima
- Hannah Cummings
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Kyowa Kirin (Japan) (JP)
- Augusta University (US)
- San Raffaele University of Rome (IT)
- Juntendo University (JP)
- Parkinson's Research and Education Foundation (US)
- University of Kansas Medical Center (US)
- IRCCS Ospedale San Raffaele (IT)
- Kyowa Kirin (France) (FR)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Toledo (US)
Publication Details
- Journal
- Journal of Movement Disorders
- Published
- 2025-04-25
- DOI
- https://doi.org/10.14802/jmd.25047
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00